HB 1809-FN - AS INTRODUCEDAMENDED SESSIONBY 26-2497THE 05/09 HOUSE BILL26Mar2026... 1809-FN AN ACT authorizing the medical use of psilocybin through a program established in the department of health and human services.

1201h SESSION 26-2497 05/09 HOUSE BILL 1809-FN AN ACT establishing a medical psilocybin advisory board to assess the advantages and disadvantages of the use of psilocybin for therapeutic purposes.

Health, Human Services and Elderly Affairs ───────────────────────────────────────────────────────────────── AMENDED ANALYSIS This bill authorizesestablishes thea medical usepsilocybin ofadvisory psilocybinboard throughto aassess programthe establishedadvantages inand disadvantages of the departmentuse of healthpsilocybin andfor humantherapeutic services.purposes.

HB 1809-FN - AS INTRODUCEDAMENDED 26-2497BY 05/09THE STATEHOUSE OF26Mar2026... NEW HAMPSHIRE In the Year of Our Lord Two Thousand Twenty-Six AN ACT authorizing the medical use of psilocybin through a program established in the department of health and human services.

1201h 26-2497 05/09 STATE OF NEW HAMPSHIRE In the Year of Our Lord Two Thousand Twenty-Six AN ACT establishing a medical psilocybin advisory board to assess the advantages and disadvantages of the use of psilocybin for therapeutic purposes.

The purpose of this act is to createstudy the feasibility of the creation of a carefully monitored and closely supervised setting in which an approved medical provider can treat a carefully chosen patient with appropriate doses of psilocybin which that same provider has produced for a medical intervention.

Medical UsePsilocybin ofAdvisory Psilocybin.Board.

Amend RSA by inserting after chapter 126-Z126- Z the following new chapter:

CHAPTER 126-ZZ MEDICALMedical USEPsilocybin OFAdvisory PSILOCYBINBoard 126-ZZ:1 Definitions.

“Provider” means an approved medical provider licensed in New Hampshire who has been approved by the department to provide medical services to qualified patientspatients. and who has been approved by the department to produce the psilocybin they will use as a provider.

“Medical“Producer" services” means servicesa providedperson towho agrows patientand inharvests anor approvedprepares settingpsilocybin before,from during,psilocybin-producing andmushrooms, afterincluding theto ingestioncompound, ofconvert, psilocybinprocess, andor includesmanufacture apsilocybin preparationproducts session,directly anor administrationindirectly sessionfrom psilocybin mushrooms and anwho integrationhas session.been approved as a provider.

“Provider" or "producer" means a person who grows and harvests or prepares psilocybin from psilocybin-producing mushrooms, including to compound, convert, process, or manufacture psilocybin products directly or indirectly from psilocybin mushrooms and who has been approved as a provider.

V.

VI.V.

HBVI. 1809-FN - AS INTRODUCED - Page 2 - VII.

“Qualified“Qualifying patient” means a patient whom a provider, as defined by RSA 126-ZZ:1, IV,II, has diagnosed a medically appropriate candidate for the use of medical psilocybin based on being diagnosed with a qualifying condition.

VIII.VII.

“Qualifying condition” includes:means any of the following:

HB 1809-FN - AS AMENDED BY THE HOUSE - Page 2 - (a) Major treatment-resistant depression;

and (d) Other conditions recommended by the advisory board to the department and approved by the department.

126-ZZ:2 Medical Use of Psilocybin Program.Advisory Board.

The department shall establish a medical use of psilocybin program that will:

ApproveThere providersis forhereby established the medical psilocybin advisory board, which shall assess the clinical, quality, and public health related advantages and disadvantages of the use of psilocybin infor therapeutic dosespurposes withunder qualifyingthis patients.chapter and, if appropriate, design a program for the medical use of psilocybin.

ApproveNotwithstanding theRSA above14:49, providersthe asboard producersshall consist of psilocybinthe infollowing therapeuticmembers: doses to qualifying patients.

III.(a) The medical director of the department of health and human services, or designee.

Compile(b) aA publicqualifying listpatient, ofappointed provider/producersby that includes the namecommissioner andof addressthe department of eachhealth provider and provider/producer.human services.

IV.(c) A representative from the veterans’ affairs community, appointed by the commissioner of the department of health and human services.

Establish(d) requirementsA forrepresentative datafrom collectionthe tohouse evaluateof therepresentatives, programappointed andby the usespeaker of bestthe practiceshouse byof provider/producers.representatives.

V.(e) A representative from the house of representatives, nominated by the minority leader of the house and appointed by the speaker of the house of representatives.

Establish(f) otherNine requirements,medical restrictions, and limitationsother throughproviders, rulesappointed promulgated by the commissioner of the department toof ensurehealth anand efficacioushuman program. services, 126-ZZ:3representing Provider/Producerthe Application.following fields:

Only a provider/producer who has received an approval by the department for the medical use of psilocybin subject to the rules established under 126-ZZ:4 shall be allowed to provide psilocybin to a qualified patient.

To receive an approval, the provider shall complete an application that:

I.

Lists the names, addresses, and birthdates of the owner of the provider’s organization or business and all those within the organization or business who will be involved in any fashion with the medical use of psilocybin.

II.

Provides the curriculum vitae of all those within the organization or business who will supervise the use of psilocybin by a qualified patient.

III.

Identifies and describes the location or locations at which the supervised medical use of psilocybin will occur.

IV.

Identifies and describes the location or locations at which the supervised production of psilocybin will occur.